Anika Therapeutics Inc. (NASDAQ:ANIK) is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.01 per share.
For the full year, analysts predict revenues of $ 130.94 million, while looking forward to loss of $ 0.22 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 160.00 million ~ $ 165.00 million
Click Here For More Historical Outlooks Of Anika Therapeutics Inc.
Previous Quarter Performance
Anika Therapeutics Inc. outlined income for the second quarter of $ 0.09 per share, from the revenue of $ 30.68 million. The quarterly earnings dropped 86.76 percent while revenues increased 0.85 percent compared with the same quarter last year.
According to street consensus, ANIK was expected to report 2Q20 loss of $ 0.24 per share from revenue of $ 20.37 million. The bottom line results beat street analysts by $ 0.33 or 137.50 percent, at the same time, top line results outshined analysts by $ 10.31 million or 50.61 percent.
Stock Performance
Shares of Anika Therapeutics Inc. traded up $ 1.92 or 5.80 percent on Tuesday, reaching $ 35.04 with volume of 134.90 thousand shares. Anika Therapeutics Inc. has traded high as $ 35.33 and has cracked $ 32.99 on the downward trend
According to the previous trading day, closing price of $ 35.04, representing a 50.48 % increase from the 52 week low of $ 22.01 and a 46.87 % decrease over the 52 week high of $ 62.34.
The company has a market capital of $ 497.83 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Anika Therapeutics Inc. will be hosting a conference call at 5:00 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.anikatherapeutics.com
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.
